Quick Answer
Edgewise Therapeutics, Inc. reported Cash and Equivalents of $61.15 million for fiscal year 2025.
Edgewise Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $61.15M | +46.8% |
| 2024 | $41.67M | -51.6% |
| 2023 | $86.10M | +291.5% |
| 2022 | $21.99M | +41.3% |
| 2021 | $15.57M | -85.2% |
| 2020 | $104.92M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $46.00M | +2.7% | +6.0% |
| June 30, 2025 | $43.40M | -0.2% | -13.1% |
| March 31, 2025 | $49.92M | +65.0% | +19.8% |
| December 31, 2024 | $41.67M | -51.6% | -7.0% |
| September 30, 2024 | $44.81M | +36.0% | +3.0% |
| June 30, 2024 | $43.48M | +36.7% | +43.7% |
| March 31, 2024 | $30.26M | -37.3% | -64.8% |
| December 31, 2023 | $86.10M | +291.5% | +161.2% |
- Edgewise Therapeutics, Inc. showed an increase of +46.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Edgewise Therapeutics, Inc.’s cash and equivalents has declined by 41.7% (from $104.92 million to $61.15 million).
- The most recent figure is from Edgewise Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: